Phase 2 Myeloma Trial, Recruiting NCT06196255 Sponsor: Xuzhou Medical University Condition: Myeloma
Back to Myeloma

Phase 2 Myeloma Trial, Recruiting

NCT06196255
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 70 years old.
  • Doctors expect you to live for more than 12 weeks.
  • You have been diagnosed with multiple myeloma confirmed through physical checks, lab tests, tissue samples, and scans.
  • Your multiple myeloma has stopped responding to treatment (refractory myeloma).
  • Your multiple myeloma has come back after previous treatment (relapsed myeloma).
  • Your liver function tests (ALT, AST, and bilirubin) are within an acceptable range (confirm with trial site).
  • Your general health and ability to carry out daily activities meets a minimum score on a standard scale (confirm with trial site).
  • You do not have serious heart, liver, kidney, or other major organ problems.
  • Your myeloma came back or did not go into remission after a stem cell transplant or immune cell therapy.
  • You are not a suitable candidate for a stem cell transplant, or you are unable to have one due to practical limitations.
  • A blood sample can be taken from your vein for a cell collection procedure, with no other reasons preventing this.
  • You understand the trial and are willing to sign a consent form.

Who may not be able to join:

  • You are pregnant, breastfeeding, or planning to become pregnant within the next six months.
  • You have an infectious disease such as HIV or active tuberculosis.
  • You have an active hepatitis B or hepatitis C infection.
  • A lab test showed that your immune cells did not respond well enough to the process needed to prepare them for treatment (confirm with trial site).
  • Your vital signs (such as heart rate or blood pressure) are abnormal and you are unable to cooperate with testing.
  • You have a mental health condition that would prevent you from cooperating with treatment or assessments.
  • You have a history of severe allergies, particularly to a substance called IL-2.
  • You currently have a serious infection (throughout the body or in one area) that requires treatment with antibiotics or similar medicines.
  • You have a severe autoimmune disease (a condition where the immune system attacks the body).
  • The trial doctors have identified another reason they feel makes joining the trial unsuitable for you (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Kailin Xu, MD.,PD., The Affiliated Hospital oh Xuzhou Medical University

Phone: 15162166166

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Xuzhou Medical University
Registry
ClinicalTrials.gov
Start date
25 December 2023
Est. completion
1 January 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov